SCIESCOPUSQ2
INVESTIGATIONAL NEW DRUGS
SPRINGER, United States
INVESTIGATIONAL NEW DRUGS is an academic journal published by SPRINGER (United States). Identifiers: ISSN 0167-6997, eISSN 1573-0646. Indexed in SCIE, SCOPUS. Metrics: JIF 2.7, CiteScore 6.9, SJR 1.074, SNIP 0.73. Subject areas: ONCOLOGY, PHARMACOLOGY & PHARMACY. tlooto lists 4,080 papers from this journal.
CiteScore
6.90
Scopus citation metric
SJR
1.074
SCImago rank
SNIP
0.73
Source normalized impact
Percentage rank
-
JIF percentile rank
Journal profile
- ISSN
- 0167-6997
- eISSN
- 1573-0646
- Abbreviation
- INVEST NEW DRUG
- Publisher
- SPRINGER
- Country
- United States
Web of Science categories
SCIEONCOLOGY, PHARMACOLOGY & PHARMACY
Scopus ASJC categories
2730 Oncology2736 Pharmacology (medical)3004 Pharmacology
Keywords
Oncology | Pharmacology & Pharmacy
Papers in this journal
Recent papers
- Characterizing the post-market safety profile of cemiplimab: a pharmacovigilance study of the FDA adverse events reporting system database.
2026
- Clinical features, treatment and outcomes of pembrolizumab induced autoimmune hemolytic anemia.
2026 · 2 citations
- Correction to: Prostate cancer cells' growth is decreased by novel MYC inhibitors.
2026
- Effector-to-target ratio as a translational bottleneck for CD33 T-cell engagers in acute myeloid leukemia: a quantitative reanalysis of AMG 330.
2026
- Clinical pharmacokinetic characteristics and the food effect of radotinib.
2026
Most cited papers
- Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors
2016 · 783 citations
- Orthotopic Metastatic Mouse Models for Anticancer Drug Discovery and Evaluation: a Bridge to the Clinic
2004 · 557 citations
- Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
2014 · 521 citations
- Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
1992 · 489 citations
- Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
2005 · 398 citations